Zenas BioPharma, Inc.
Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases. Its pipeline includes obexelimab, orelabrutinib, ZB021, ZB022, ZB002, ZB004, and partnered regional programs such as ZB001 in greater China.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaCore clinical and partnered assets centered on obexelimab and orelabrutinib for autoimmune and I&I diseases.
Discovery and IND-enabling assets including ZB021 and ZB022 aimed at future clinical entry.
Additional proprietary I&I candidates such as ZB002 and ZB004 that may be advanced with partners.
Licensed or sublicensed programs such as ZB001/VRDN-001 in greater China.
Asiakkaat
Zenas primarily serves pharmaceutical partners, licensees, and collaboration counterparties rather than end patients directly. Its commercial model is built around out-licensing, regional sublicensing, and future commercialization of approved therapies in the U.S. and Europe. If products are approved, hospitals, specialists, and healthcare systems would become the end-market buyers through prescription and reimbursement channels.
Companies such as BMS, Zai, Tenacia, and other collaborators that buy regional rights, development access, or royalty streams.
Rheumatologists, immunologists, and other specialists who would prescribe approved I&I therapies.
Insurers and healthcare systems that influence uptake through reimbursement and formulary access.
CROs, CMOs, and research sites that support development, manufacturing, and trial execution.
Strategia
Zenas is building an immunology-focused pipeline through product candidate acquisition, internal development, and selective partnering. The company’s model combines global rights on some assets with regional out-licensing on others, while preparing for eventual self-commercialization in core Western markets.
It is the most advanced asset and the anchor for future commercialization and royalty economics.
New assets broaden the immunology platform and create future clinical optionality.
Out-licensing can reduce capital needs while preserving upside through royalties and milestones.
Direct commercialization would allow Zenas to capture more value if lead assets are approved.
Maantiede
Zenas is headquartered in the United States and expects to build commercialization capabilities in the U.S. and Europe if products are approved. Its current development and partnering footprint also extends into Asia, including Japan, South Korea, Taiwan, Hong Kong, Singapore, Australia, and greater China through regional agreements.
Riskit
Zenas faces the typical risks of a clinical-stage biopharma company: clinical failure, regulatory setbacks, and the need for substantial external funding before product sales begin. Its reliance on third-party CMOs, collaboration partners, and regional licensees also creates execution and supply-chain risk across multiple geographies.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Pipeline assets may not show sufficient efficacy or safety to advance or win approval.
Kohdistuu - Capital raising and dilutionVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company expects to fund operations externally until meaningful product revenue exists.
Kohdistuu: Corporate-wide
- Manufacturing and supply disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Clinical and future commercial supply depends on third-party CMOs and partners.
Kohdistuu - Partner concentration and regional executionVaikutus: KorkeaTodennäköisyys: Matala
Out-licensed territories and sublicenses reduce direct control over development and commercialization.
Kohdistuu - Cybersecurity and geopolitical disruptionVaikutus: KeskitasoTodennäköisyys: Matala
Clinical data, remote work, and third-party systems can be disrupted by attacks or conflicts.
Kohdistuu: Global operations and trial infrastructure
Kirjanpito
Harkinnanvaraiset erätUpfront fees, technology transfer, milestones, and royalties may be recognized in different periods.
Vaikutus: Can create volatile revenue unrelated to current operating scale
Clinical trial and CMO invoices often arrive after services are performed, requiring estimates.
Vaikutus: Affects quarterly R&D expense and operating loss
Preferred stock, convertible notes, and other financing features may require valuation judgments.
Vaikutus: Can affect reported equity and non-cash gains or losses
Pipeline assets and rights depend on future technical and commercial success.
Vaikutus: Potential write-downs if programs underperform
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Zentalis Pharmaceuticals, Inc.
ZNTL · Pharmaceutical Preparations
Zentalis Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule cancer therapies.
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
Denali Therapeutics Inc.
DNLI · Biological Products, (No Diagnostic Substances)
Denali Therapeutics is a clinical-stage biopharmaceutical company developing barrier-crossing therapeutics for neurodegenerative and lysosomal storage diseases.
Matinas BioPharma Holdings, Inc.
MTNB · Pharmaceutical Preparations
Zura Bio Ltd
ZURA · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for immune-mediated diseases.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Päivitetty: 24.9.2026